MedPath

Innovative Approach to Reduce Lung Cancer Stigma

Not Applicable
Completed
Conditions
Stigma, Social
Stigmatization
Acceptance Processes
Lung Cancer Stigma
Lung Cancer
Interventions
Behavioral: ACT-LCS Therapy
Registration Number
NCT03750864
Lead Sponsor
University of Arizona
Brief Summary

This is a feasibility study examining the feasibility and acceptability of a novel psychotherapy intervention on lung cancer patients who are experiencing stigma.

Detailed Description

Experiences of stigma (perception and internalization of negative appraisal and devaluation from others) are pervasive for lung cancer patients. Previous work has shown associations between lung cancer stigma and detriments in clinically relevant outcomes such as depression, lower quality of life, and reduced engagement in cancer care.

The investigators previously developed Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma. ACT-LCS is based in Acceptance and Commitment Therapy (ACT), a cognitive-behavioral treatment that promotes psychological flexibility through acceptance and valued direction.

This is a feasibility study examining the feasibility and acceptability of ACT-LCS.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • Proficiency in English
  • Diagnosed with or treated for Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) within the prior 12 months.
  • Scores of 37.5 on the Lung Cancer Stigma Inventory (LCSI) screening measure
Exclusion Criteria
  • Not proficient in English

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ACT-LCS TherapyACT-LCS TherapyIntervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
Primary Outcome Measures
NameTimeMethod
Number of individuals who consent to the intervention10 months

This measure will be calculated as a function of those eligible and approached who consented to the intervention. It will be utilized as a metric of feasibility and acceptability.

Number of sessions that each consented patient attended10 months

This measure will be calculated as a count of sessions that each consented participant attended. It will be utilized as a metric of acceptability of the intervention among consented participants.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

University of Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath